Pharmacokinetics of Danofloxacin in Gushi Chickens after Single Oral and Intravenous Administration
-
Published:2023-08-02
Issue:8
Volume:13
Page:906
-
ISSN:2218-1989
-
Container-title:Metabolites
-
language:en
-
Short-container-title:Metabolites
Author:
Chen Jun-Cheng1, Yang Fang1, Li Guang-Hui2, Duan Ming-Hui1, Li Ze-En1, Dai Yan1, Zhang Mei1, Yang Fan1ORCID
Affiliation:
1. College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China 2. Shantou Customs District Technology Center, Shantou 515031, China
Abstract
This study aimed to determine the pharmacokinetics of danofloxacin in Gushi chickens after a single oral (PO) and intravenous (IV) dose at 5 mg/kg body weight (BW). Thirty-two Gushi chickens, aged 20 weeks, were selected and divided into two groups at random, with each group consisting of 16 chickens, evenly distributed between males and females. Following danofloxacin administration, blood samples were taken at predetermined time intervals and the plasma was separated. The concentrations of danofloxacin in plasma were quantified by HPLC with a fluorescence detector. Then the concentrations versus time data were subjected to non-compartmental analysis (NCA) using Phoenix software (version: 8.1.0). After administering danofloxacin orally at a dose of 5 mg/kg BW to Gushi chickens, our results demonstrated that the peak concentration reached 0.53 μg/mL at 4 h. The half-life of absorption (t1/2ka) was determined to be 2.37 ± 1.60 h, and the bioavailability (F) was calculated as 40.12 ± 15.83%. For both oral and intravenous administration, the area under the concentration–time curve (AUC0-∞) was determined to be 4.72 ± 1.86 and 11.76 ± 3.25 h·µg/mL, respectively. The corresponding elimination half-life (t1/2λz) was measured as 11.24 ± 3.90 and 10.17 ± 3.72 h. Moreover, the mean residence time (MRT) was calculated as 10.20 ± 2.47 and 7.05 ± 1.97 h for these respective routes. Based on the calculated AUC/MIC ratio values, it can be inferred that the 5 mg/kg BW dosage of danofloxacin, whether administered orally or intravenously, is expected to effectively treat Escherichia coli and Pasteurella multocida infections in Gushi chickens.
Funder
Natural Science Foundation of Henan Foundation for the University Young Key Teacher Program of Henan Province
Subject
Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference32 articles.
1. Yuan, P., Zhao, Y., Li, H., Li, S., Fan, S., Zhai, B., Li, Y., Han, R., Liu, X., and Tian, Y. (2022). CircRNAs related to breast muscle development and their interaction regulatory network in Gushi chicken. Genes, 13. 2. Differentially expressed lncRNAs related to the development of abdominal fat in Gushi chickens and their interaction regulatory network;Zhai;Front. Genet.,2021 3. Song, Z., Xiao, Z., Fan, X., Zhuang, H., Li, Y., Zhu, J., Zhao, D., Paerhati, M., and Suo, D. (2023). Multiresidue determination of 26 quinolones in poultry feathers using UPLC-MS/MS and their application in residue monitoring. Molecules, 28. 4. Pharmacokinetics and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous, intramuscular, subcutaneous, and oral administrations;Corum;J. Vet. Pharmacol. Ther.,2019 5. Ural, M.N., and Uney, K. (2021). Pharmacokinetic behavior and Pharmacokinetic/Pharmacodynamic integration of danofloxacin following single or co-administration with meloxicam in healthy lambs and lambs with respiratory infections. Antibiotics, 10.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|